Cost-effectiveness of rosuvastatin for primary prevention of cardiovascular events according to framingham risk score in patients with elevated C-reactive protein gary

Journal of the American Osteopathic Association

Volumn 110, Issue 8, 2010, Pages 427-435

  MacDonald, Gary P ^a  

^a Family Medicine Residency Program   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; FLUOROBENZENE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PYRIMIDINE DERIVATIVE; ROSUVASTATIN; SULFONAMIDE;

ARTICLE; CARDIOVASCULAR DISEASE; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; DIAGNOSIS RELATED GROUP; DRUG EFFECT; ECONOMICS; FOOD AND DRUG ADMINISTRATION; HUMAN; HYPERCHOLESTEROLEMIA; METHODOLOGY; PRIMARY PREVENTION; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; RISK ASSESSMENT; STATISTICAL MODEL; UNITED STATES;

C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; COST-BENEFIT ANALYSIS; DIAGNOSIS-RELATED GROUPS; FLUOROBENZENES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MARKOV CHAINS; MODELS, STATISTICAL; PRIMARY PREVENTION; PYRIMIDINES; QUALITY-ADJUSTED LIFE YEARS; RISK ASSESSMENT; SOUTH DAKOTA; SULFONAMIDES; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 79952279050     PISSN: 00986151     EISSN: 00986151     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. American Heart Association. Heart Disease & Stroke Statistics. 2009 Update At-A-Glance. Dallas, Texas: American Heart Association; 2009. http://www.americanheart.org/downloadable/heart/1240250946756LS1982%20Heart%20and%20Stroke%20Update.042009.pdf. Accessed July 15, 2010.
2. Expert Panel on the Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on the Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486-2497.
3. Scirica BM, Morrow DA. Is C-reactive protein an innocent bystander or proatherogenic culprit? The verdict is still out. Circulation. 2006;113(17): 2128-2151. http://circ.ahajournals.org/cgi/reprint/113/17/2128. Accessed July 17, 2010.
4. Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004;350(14): 1387-1397. http://content.nejm.org/cgi/reprint/350/14/1387.pdf. Accessed July 17, 2010.
5. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336(14): 973-979. http://content.nejm.org/cgi/reprint/336/14/973.pdf. Accessed July 17, 2010.
6. Levinson S. Inflammatory and long-term risk markers. Clin Lab Med. 2006;26(3):553-570.
7. Koenig W, Sund M, Frohlich M, et al. C-reactive protein, a sensitive markerhealthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg cohort study, 1984 to 1992. Circulation. 1999;99(2): 237-242. http://circ.ahajournals.org/cgi/reprint/99/2/237.pdf. Accessed July 17, 2010.
8. Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol. 1999;19(4): 972-978. http://atvb.ahajournals.org/cgi/reprint/19/4/972. Accessed July 17, 2010.
9. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001;286(3):327-334.
10. Shamsuzzaman ASM, Winnicki M, Lanfranchi P, Wolk R, Kara T, Accurso V, et al. Elevated C-reactive protein in patients with obstructive sleep apnea. Circulation. 2002;105(21): 2462-2464. http://www.circ.ahajournals.org/cgi/reprint/105/21/2462. Accessed July 17, 2010.
11. Sesso HD, Buring JE, Rifai N, Blake GJ, Gaziano JM, Ridker PM. C-reactive protein and the risk of developing hypertension. JAMA. 2003;290(22): 2945-2951.
12. Rutter MK, Meigs JB, Sullivan LM, D'Agostino RB Sr, Wilson PWF. C reactive protein, the metabolic syndrome, and prediction of cardiocardiovascular events in the Framingham Offspring Study. Circulation. 2004;110(4): 380-385. http://www.circ.ahajournals.org/cgi/reprint/110/4/380. Accessed July 17, 2010.
13. Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, et al; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005;352(1): 20-28. http://content.nejm.org/cgi/reprint/352/1/20.pdf. Accessed July 17, 2010.
14. Ridker PM, Danielson E, Fonseca FAH, Genest J, Gotto AM, Kastelein JJP, et al; for the JUPITER Study Group. Rosuvastatin to prevent cardiovascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21): 2195-2207. http://content.nejm.org/cgi/reprint/359/21/2195.pdf. Accessed July 17, 2010.
15. FDA approves new indication for Crestor [press release]. Washington, DC: US Food and Drug Administration; February 9, 2010. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm200128.htm. Accessed July 17, 2010.
16. Woloshin S, Schwartz LM, Kerin K, Welch HG. Estimating the impact of adding C-reactive protein as a criterion for lipid lowering treatment in the United States. J Gen Intern Med. 2007;22(2):197-204.
17. Ganz DA, Kuntz KM, Jacobson GA, Avorn J. Cost-effectiveness of 3- hydroxy-3-methylglutaryl coenzyme A reductase inhibitor therapy in older patients with myocardial infarction. Ann Intern Med. 2000;132(10): 780-787. http://www.annals.org/content/132/10/780.1.full.pdf+html. Accessed July 17, 2010.
18. Van Hout BA, Simoons ML. Cost-effectiveness of HMG coenzyme reductase inhibitors. Eur Heart J. 2001;22(9): 751-761. http://eurheartj.oxfordjournals.org/cgi/reprint/22/9/751. Accessed July 17, 2010.
19. D'Agostino RB, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008;117(6): 743-753. http://circ.ahajournals.org/cgi/content/full/117/6/743. Accessed July 17, 2010.
20. Ridker PM, Paynter NP, Rifai N, Gaziano M, Cook NR. C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men. Circulation. 2008;118(22): 2243-2251. http://www.circ.ahajournals.org/cgi/reprint/118/22/2243. Accessed July 17, 2010.
21. Ridker PM, Buring JE, Rifai N, Cook NR. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA. 2007;297(6):611-619.
22. Crestor (rosuvastatin calcium). Highlights of prescribing information. AstraZeneca Web site, revised June 2010. http://www1.astrazenecaus.com/pi/crestor.pdf.Accessed June 17, 2010.
23. Red Book 2009: Pharmacy's Fundamental Reference. 113th ed. New York City, NY: Thomson Reuters; 2009.
24. Physician fee schedule relative value files, 2009. Centers for Medicare & Medicaid Services Web site. http://www.cms.hhs.gov/PhysicianFeeSched/PFSRVF/list.asp. Accessed December 3, 2009.
25. Clinical laboratory fee schedule, 2009. Centers for Medicare & Medicaid Services Web site. http://www.cms.hhs.gov/ClinicalLabFeesched/02_clinlab.asp.Accessed May 20, 2009.
26. Acute inpatient prospective payment system-overview, March 1, 2009. Centers for Medicare & Medicaid Services Web site. http://www.cms.gov/AcuteInpatientPPS/01_overview.asp#TopOfPage. Accessed March 5, 2009.
27. Centers for Medicare & Medicaid Services Medicare Program. Hospital Inpatient Prospective Payment Systems and Fiscal Year 2009 Rates: Final Fiscal Year 2009 Wage Indices and Payment Rates Including Implementation of Section 124 of the Medicare Improvement for Patients and Providers Act of 2008. Notice. College Park, MD: National Archives and Records Administration,Federal Register; October 2008: 130. FR document no. E8-23083.
28. Sullivan PW, Ghushchyan V. Preference-based EQ-5D index scores for chronic conditions in the United States. Med Decis Making. 2006;26(4): 410- 420. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2634296/pdf/nihms-81406.pdf. Accessed July 17, 2010.
29. Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomized statin trials [published online ahead of print February 16, 2010]. Lancet. 2010;375(9716):735-742.
30. Pletcher MJ, Lazar L, Bibbins-Domingo K, Moran A, Rodondi N, Coxson P, et al. Comparing impact and cost-effectiveness of primary prevention strategies for lipid-lowering. Ann Intern Med. 2009;150(4): 243-254 http://www.annals.org/content/150/4/243.full.pdf+html. Accessed July 17, 2010.
31. CRESTOR patent upheld by US court [press release]. Wilmington, DE: AstraZeneca; June 30, 2010. http://www.astrazeneca.com/search/?itemId=9833512.AccessedJuly26,2010.